<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35563846</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>To Detach, Migrate, Adhere, and Metastasize: CD97/<i>ADGRE5</i> in Cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1538</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11091538</ELocationID>
        <Abstract>
          <AbstractText>Tumorigenesis is a multistep process, during which cells acquire a series of mutations that lead to unrestrained cell growth and proliferation, inhibition of cell differentiation, and evasion of cell death. Growing tumors stimulate angiogenesis, providing them with nutrients and oxygen. Ultimately, tumor cells invade the surrounding tissue and metastasize; a process responsible for about 90% of cancer-related deaths. Adhesion G protein-coupled receptors (aGPCRs) modulate the cellular processes closely related to tumor cell biology, such as adhesion and detachment, migration, polarity, and guidance. Soon after first being described, individual human aGPCRs were found to be involved in tumorigenesis. Twenty-five years ago, CD97/<i>ADGRE5</i> was discovered to be induced in one of the most severe tumors, dedifferentiated anaplastic thyroid carcinoma. After decades of research, the time has come to review our knowledge of the presence and function of CD97 in cancer. In summary, CD97 is obviously induced or altered in many tumor entities; this has been shown consistently in nearly one hundred published studies. However, its high expression at circulating and tumor-infiltrating immune cells renders the systemic targeting of CD97 in tumors difficult.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Aust</LastName>
            <ForeName>Gabriela</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Research Laboratories of the Clinic of Visceral, Transplantation, Thoracic, and Vascular Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Laboratories of the Clinic of Orthopedics, Traumatology and Plastic Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Leyu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Research Laboratories of the Clinic of Orthopedics, Traumatology and Plastic Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quaas</LastName>
            <ForeName>Marianne</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-2781-1968</Identifier>
            <AffiliationInfo>
              <Affiliation>Research Laboratories of the Clinic of Visceral, Transplantation, Thoracic, and Vascular Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C095004">ADGRE5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ADGRE5</Keyword>
        <Keyword MajorTopicYN="N">CD97</Keyword>
        <Keyword MajorTopicYN="N">EGF-TM7</Keyword>
        <Keyword MajorTopicYN="N">aGPCR</Keyword>
        <Keyword MajorTopicYN="N">angiogenesis</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">invasion</Keyword>
        <Keyword MajorTopicYN="N">metastasis</Keyword>
        <Keyword MajorTopicYN="N">migration</Keyword>
        <Keyword MajorTopicYN="N">tumor</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35563846</ArticleId>
        <ArticleId IdType="pmc">PMC9101421</ArticleId>
        <ArticleId IdType="doi">10.3390/cells11091538</ArticleId>
        <ArticleId IdType="pii">cells11091538</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Austyn J.M., Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur. J. Immunol. 1981;11:805–815. doi: 10.1002/eji.1830111013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.1830111013</ArticleId>
            <ArticleId IdType="pubmed">7308288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichler W., Aust G., Hamann D. Characterization of the early activation-dependent antigen on lymphocytes defined by the monoclonal antibody BL-Ac(F2) Scand. J. Immunol. 1994;39:111–115. doi: 10.1111/j.1365-3083.1994.tb03348.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-3083.1994.tb03348.x</ArticleId>
            <ArticleId IdType="pubmed">8290889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann J., Eichler W., Hamann D., Kerstens H.M., Poddighe P.J., Hoovers J.M., Hartmann E., Strauss M., van Lier R.A. Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J. Immunol. 1995;155:1942–1950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7636245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pickl W.F., Majdic O., Mai I., Gadd S., Knapp W.  Overview of CD97. In: Schlossman S.F., Boumsell L., Gilks W., Halan J.M., Morimoto C., Ritz J., Shaw S., Silverstein R., Springer T., Tedder T.F., et al., editors. Leucocyte Typing V. Oxford University Press; Oxford, UK: New York, NY, USA: Tokyo, Japan: 1995. pp. 1151–1153.</Citation>
        </Reference>
        <Reference>
          <Citation>Carver E.A., Hamann J., Olsen A.S., Stubbs L. Physical mapping of EMR1 and CD97 in human chromosome 19 and assignment of CD97 to mouse chromosome 8 suggest an ancient genomic duplication. Mamm. Genome. 1999;10:1039–1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10501980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H.H., Stacey M., Hamann J., Gordon S., McKnight A.J. Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics. 2000;67:188–200. doi: 10.1006/geno.2000.6238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/geno.2000.6238</ArticleId>
            <ArticleId IdType="pubmed">10903844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stacey M., Lin H.H., Hilyard K.L., Gordon S., McKnight A.J. Human epidermal growth factor (EGF) module-containing mucin-like hormone receptor 3 is a new member of the EGF-TM7 family that recognizes a ligand on human macrophages and activated neutrophils. J. Biol. Chem. 2001;276:18863–18870. doi: 10.1074/jbc.M101147200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M101147200</ArticleId>
            <ArticleId IdType="pubmed">11279179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKnight A.J., Gordon S. EGF-TM7: A novel subfamily of seven-transmembran-region leukocyte cell-surface molecules. Immunol. Today. 1996;17:283–287. doi: 10.1016/0167-5699(96)80546-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0167-5699(96)80546-9</ArticleId>
            <ArticleId IdType="pubmed">8962632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwakkenbos M.J., Kop E.N., Stacey M., Matmati M., Gordon S., Lin H.H., Hamann J. The human EGF-TM7 family: A postgenomic view. Immunogenetics. 2004;55:655–666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14647991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 2003;63:1256–1272. doi: 10.1124/mol.63.6.1256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.63.6.1256</ArticleId>
            <ArticleId IdType="pubmed">12761335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schioth H.B., Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen. Comp. Endocrinol. 2005;142:94–101. doi: 10.1016/j.ygcen.2004.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygcen.2004.12.018</ArticleId>
            <ArticleId IdType="pubmed">15862553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander S.P., Christopoulos A., Davenport A.P., Kelly E., Mathie A., Peters J.A., Veale E.L., Armstrong J.F., Faccenda E., Harding S.D., et al.  The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br. J. Pharmacol. 2021;178((Suppl. 1)):S27–S156. doi: 10.1111/bph.15538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.15538</ArticleId>
            <ArticleId IdType="pubmed">34529832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Frederiksson R., Hall R.A., Harty B.L., Kirchhoff C., Knapp B., et al.  International Union of Basic and Clinical Pharmacology. XCI. Adhesion G protein-coupled receptors. Pharmacol. Rev. 2015;67:338–367. doi: 10.1124/pr.114.009647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.114.009647</ArticleId>
            <ArticleId IdType="pmc">PMC4394687</ArticleId>
            <ArticleId IdType="pubmed">25713288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray J.X., Haino M., Roth M.J., Maguire J.E., Jensen P.N., Yarme A., Stetler-Stevenson M.A., Siebenlist U., Kelly K. CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J. Immunol. 1996;157:5438–5447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8955192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wobus M., Vogel B., Schmücking E., Hamann J., Aust G. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int. J. Cancer. 2004;112:815–822. doi: 10.1002/ijc.20483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.20483</ArticleId>
            <ArticleId IdType="pubmed">15386373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aust G., Wandel E., Boltze C., Sittig D., Schütz A., Horn L.C., Wobus M. Diversity of CD97 in smooth muscle cells (SMCs) Cell Tissue Res. 2006;323:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16163489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zyryanova T., Schneider R., Adams V., Sittig D., Kerner C., Gebhardt C., Ruffert H., Glasmacher S., Hepp P., Punkt K., et al.  Skeletal muscle expression of the adhesion-GPCR CD97: CD97 deletion induces an abnormal structure of the sarcoplasmatic reticulum but does not impair skeletal muscle function. PLoS ONE. 2014;9:e100513.  doi: 10.1371/journal.pone.0100513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0100513</ArticleId>
            <ArticleId IdType="pmc">PMC4065095</ArticleId>
            <ArticleId IdType="pubmed">24949957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T., Ward Y., Tian L., Lake R., Guedez L., Stetler-Stevenson W.G., Kelly K. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counter receptors on endothelial cells. Blood. 2004;105:2836–2844. doi: 10.1182/blood-2004-07-2878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2004-07-2878</ArticleId>
            <ArticleId IdType="pubmed">15576472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tjong W.Y., Lin H.H. The role of the RGD motif in CD97/ADGRE5-and EMR2/ADGRE2-modulated tumor angiogenesis. Biochem. Biophys. Res. Commun. 2019;520:243–249. doi: 10.1016/j.bbrc.2019.09.113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.09.113</ArticleId>
            <ArticleId IdType="pubmed">31594642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tjong W.Y., Lin H.H. The RGD motif is involved in CD97/ADGRE5-promoted cell adhesion and viability of HT1080 cells. Sci. Rep. 2019;9:1517. doi: 10.1038/s41598-018-38045-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-38045-w</ArticleId>
            <ArticleId IdType="pmc">PMC6365523</ArticleId>
            <ArticleId IdType="pubmed">30728423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liebscher I., Schon J., Petersen S.C., Fischer L., Auerbach N., Demberg L.M., Mogha A., Coster M., Simon K.U., Rothemund S., et al.  A tethered agonist within the ectodomain activates the adhesion G protein-coupled receptors GPR126 and GPR133. Cell Rep. 2014;9:2018–2026. doi: 10.1016/j.celrep.2014.11.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.11.036</ArticleId>
            <ArticleId IdType="pmc">PMC4277498</ArticleId>
            <ArticleId IdType="pubmed">25533341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okajima D., Kudo G., Yokota H. Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by proteolytic processing. J. Recept. Signal Transduct. 2010;30:143–153. doi: 10.3109/10799891003671139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10799891003671139</ArticleId>
            <ArticleId IdType="pubmed">20367554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward Y., Lake R., Yin J.J., Heger C.D., Raffeld M., Goldsmith P.K., Merino M., Kelly K. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. 2011;71:7301–7311. doi: 10.1158/0008-5472.CAN-11-2381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2381</ArticleId>
            <ArticleId IdType="pmc">PMC6697138</ArticleId>
            <ArticleId IdType="pubmed">21978933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paavola K.J., Stephenson J.R., Ritter S.L., Alter S.P., Hall R.A. The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. J. Biol. Chem. 2011;286:28914–28921. doi: 10.1074/jbc.M111.247973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.247973</ArticleId>
            <ArticleId IdType="pmc">PMC3190698</ArticleId>
            <ArticleId IdType="pubmed">21708946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilbig D., Sittig D., Hoffmann F., Rothemund S., Warmt E., Quaas M., Sturmer J., Seiler L., Liebscher I., Hoang N.A., et al.  Mechano-dependent phosphorylation of the PDZ-binding motif of CD97/ADGRE5 modulates cellular detachment. Cell Rep. 2018;24:1986–1995. doi: 10.1016/j.celrep.2018.07.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.07.071</ArticleId>
            <ArticleId IdType="pubmed">30134161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beliu G., Altrichter S., Guixà-González R., Hemberger M., Brauer I., Dahse A.-K., Scholz N., Wieduwild R., Kuhlemann A., Batebi H., et al.  Tethered agonist exposure in intact adhesion/class B2 GPCRs through intrinsic structural flexibility of the GAIN domain. Mol. Cell. 2021;81:905–921.e5. doi: 10.1016/j.molcel.2020.12.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2020.12.042</ArticleId>
            <ArticleId IdType="pubmed">33497605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn H.A., Ferguson S.S. PDZ protein regulation of G protein-coupled receptor trafficking and signaling pathways. Mol. Pharmacol. 2015;88:624–639. doi: 10.1124/mol.115.098509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.115.098509</ArticleId>
            <ArticleId IdType="pubmed">25808930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann J., Vogel B., van Schijndel G.M., van Lier R.A. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF) J. Exp. Med. 1996;184:1185–1189. doi: 10.1084/jem.184.3.1185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.184.3.1185</ArticleId>
            <ArticleId IdType="pmc">PMC2192782</ArticleId>
            <ArticleId IdType="pubmed">9064337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wandel E., Saalbach A., Sittig D., Gebhardt C., Aust G. Thy-1 (CD90) is an interaction partner for CD97 on activated endothelial cells. J. Immunol. 2012;188:1442–1450. doi: 10.4049/jimmunol.1003944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1003944</ArticleId>
            <ArticleId IdType="pubmed">22210915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwakkenbos M.J., Pouwels W., Matmati M., Stacey M., Lin H.H., Gordon S., van Lier R.A., Hamann J. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J. Leukoc. Biol. 2005;77:112–119. doi: 10.1189/jlb.0704402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0704402</ArticleId>
            <ArticleId IdType="pubmed">15498814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrant L.G., Chapman M.A., Buckley D.J., Spendlove I., Robins R.A., Armitage N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 2003;52:638–642. doi: 10.1007/s00262-003-0402-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-003-0402-y</ArticleId>
            <ArticleId IdType="pubmed">12811528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Chen L., Peng S., Chen Z., Gimm O., Finke R., Hoang-Vu C. The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol. Rep. 2005;14:1413–1420. doi: 10.3892/or.14.6.1413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.14.6.1413</ArticleId>
            <ArticleId IdType="pubmed">16273233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loberg R.D., Wojno K.J., Day L.L., Pienta K.J. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology. 2005;66:1321–1326. doi: 10.1016/j.urology.2005.06.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urology.2005.06.094</ArticleId>
            <ArticleId IdType="pubmed">16360477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S.L., Xu C., Wu X.L., Li J.L., Liu Z., Zeng Q.Q. The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int. J. Colorectal Dis. 2010;25:695–702. doi: 10.1007/s00384-010-0926-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00384-010-0926-5</ArticleId>
            <ArticleId IdType="pubmed">20339853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Z., Wu H., Jiao Y., Zheng J. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. Oncol. Lett. 2015;9:793–797. doi: 10.3892/ol.2014.2751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2014.2751</ArticleId>
            <ArticleId IdType="pmc">PMC4301556</ArticleId>
            <ArticleId IdType="pubmed">25624904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y., Wang W., Xu L., Li L., Liu J., Feng M., Bu H. Immunohistochemical expression and prognostic significance of CD97 and its ligand DAF in human cervical squamous cell carcinoma. Int. J. Gynecol. Pathol. 2015;34:473–479. doi: 10.1097/PGP.0000000000000200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PGP.0000000000000200</ArticleId>
            <ArticleId IdType="pubmed">26107567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z.-W., Liu M.-C., Hong H.-J., Du Q., Chen Y.-L. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumour Biol. 2017;39:1010428317694319. doi: 10.1177/1010428317694319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1010428317694319</ArticleId>
            <ArticleId IdType="pubmed">28345461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin Y., Xu X., Tang J., Zhang W., Zhangyuan G., Ji J., Deng L., Lu S., Zhuo H., Sun B. CD97 promotes tumor aggressiveness through the traditional G protein-coupled receptor-mediated signaling in hepatocellular carcinoma. Hepatology. 2018;68:1865–1878. doi: 10.1002/hep.30068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.30068</ArticleId>
            <ArticleId IdType="pubmed">29704239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann J., Hsiao C.C., Lee C.S., Ravichandran K.S., Lin H.H. Adhesion GPCRs as modulators of immune cell function. Handb. Exp. Pharmacol. 2016;234:329–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerny O., Godlee C., Tocci R., Cross N.E., Shi H., Williamson J.C., Alix E., Lehner P.J., Holden D.W. CD97 stabilises the immunological synapse between dendritic cells and T cells and is targeted for degradation by the Salmonella effector SteD. PLoS Pathog. 2021;17:e1009771.  doi: 10.1371/journal.ppat.1009771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1009771</ArticleId>
            <ArticleId IdType="pmc">PMC8345877</ArticleId>
            <ArticleId IdType="pubmed">34314469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D., Wu J., Zhu H., Zhu X., Jin Y., Yu Y., Zhang X. Treatment of microvascular invasion in hepatocellular carcinoma with drug-loaded nanocomposite platform under synergistic effect of magnetic field/near-infrared light. J. Biomed. Mater. Res. B Appl. Biomater. 2021;110:712–724. doi: 10.1002/jbm.b.34950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbm.b.34950</ArticleId>
            <ArticleId IdType="pubmed">34664385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karpus O.N., Veninga H., Hoek R.M., Flierman D., van Buul J.D., Vandenakker C.C., vanBavel E., Medof M.E., van Lier R.A., Reedquist K.A., et al.  Shear stress-dependent downregulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55. J. Immunol. 2013;190:3740–3748. doi: 10.4049/jimmunol.1202192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1202192</ArticleId>
            <ArticleId IdType="pubmed">23447688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D., Duan L., Rodda L.B., Lu E., Xu Y., An J., Qiu L., Liu F., Looney M.R., Yang Z., et al.  CD97 promotes spleen dendritic cell homeostasis through the mechanosensing of red blood cells. Science. 2022;375:eabi5965. doi: 10.1126/science.abi5965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abi5965</ArticleId>
            <ArticleId IdType="pubmed">35143305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauzay C., Voutetakis K., Chatziioannou A., Chevet E., Avril T. CD90/Thy-1, a cancer-associated cell surface signaling molecule. Front. Cell Dev. Biol. 2019;7:66. doi: 10.3389/fcell.2019.00066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00066</ArticleId>
            <ArticleId IdType="pmc">PMC6497726</ArticleId>
            <ArticleId IdType="pubmed">31080802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward Y., Lake R., Martin P.L., Killian K., Salerno P., Wang T., Meltzer P., Merino M., Cheng S.Y., Santoro M., et al.  CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene. 2013;32:2726–2738. doi: 10.1038/onc.2012.301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.301</ArticleId>
            <ArticleId IdType="pmc">PMC7561260</ArticleId>
            <ArticleId IdType="pubmed">22797060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward Y., Lake R., Faraji F., Sperger J., Martin P., Gilliard C., Ku K.P., Rodems T., Niles D., Tillman H., et al.  Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinates transendothelial migration. Cell Rep. 2018;23:808–822. doi: 10.1016/j.celrep.2018.03.092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.03.092</ArticleId>
            <ArticleId IdType="pmc">PMC6574118</ArticleId>
            <ArticleId IdType="pubmed">29669286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker S., Wandel E., Wobus M., Schneider R., Amasheh S., Sittig D., Kerner C., Naumann R., Hamann J., Aust G. Overexpression of CD97 in intestinal epithelial cells of transgenic mice attenuates colitis by strengthening adherens junctions. PLoS ONE. 2010;5:e8507.  doi: 10.1371/journal.pone.0008507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0008507</ArticleId>
            <ArticleId IdType="pmc">PMC2801611</ArticleId>
            <ArticleId IdType="pubmed">20084281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aust G., Kerner C., Gonsior S., Sittig D., Schneider H., Buske P., Scholz M., Dietrich N., Oldenburg S., Karpus O.N., et al.  Mice overexpressing CD97 in intestinal epithelial cells provide a unique model for mammalian postnatal intestinal cylindrical growth. Mol. Biol. Cell. 2013;24:2256–2268. doi: 10.1091/mbc.e13-04-0175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.e13-04-0175</ArticleId>
            <ArticleId IdType="pmc">PMC3708731</ArticleId>
            <ArticleId IdType="pubmed">23676664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilbig D., Dietrich N., Wandel E., Gonsior S., Sittig D., Hamann J., Aust G. The interaction of CD97/ADGRE5 with beta-catenin in adherens junctions is lost during colorectal carcinogenesis. Front. Oncol. 2018;8:182. doi: 10.3389/fonc.2018.00182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2018.00182</ArticleId>
            <ArticleId IdType="pmc">PMC5980956</ArticleId>
            <ArticleId IdType="pubmed">29888202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholz N., Gehring J., Guan C., Ljaschenko D., Fischer R., Lakshmanan V., Kittel R.J., Langenhan T. The Adhesion GPCR Latrophilin/CIRL shapes mechanosensation. Cell Rep. 2015;11:866–874. doi: 10.1016/j.celrep.2015.04.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.04.008</ArticleId>
            <ArticleId IdType="pubmed">25937282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen S.C., Luo R., Liebscher I., Giera S., Jeong S.J., Mogha A., Ghidinelli M., Feltri M.L., Schoneberg T., Piao X., et al.  The adhesion GPCR GPR126 has distinct, domain-dependent functions in Schwann cell development mediated by interaction with laminin-211. Neuron. 2015;85:755–769. doi: 10.1016/j.neuron.2014.12.057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2014.12.057</ArticleId>
            <ArticleId IdType="pmc">PMC4335265</ArticleId>
            <ArticleId IdType="pubmed">25695270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyden S.E., Desai A., Cruse G., Young M.L., Bolan H.C., Scott L.M., Eisch A.R., Long R.D., Lee C.C., Satorius C.L., et al.  Vibratory urticaria associated with a missense variant in ADGRE2. N. Engl. J. Med. 2016;374:656–663. doi: 10.1056/NEJMoa1500611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1500611</ArticleId>
            <ArticleId IdType="pmc">PMC4782791</ArticleId>
            <ArticleId IdType="pubmed">26841242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilde C., Fischer L., Lede V., Kirchberger J., Rothemund S., Schöneberg T., Liebscher I. The constitutive activity of the adhesion GPCR GPR114/ADGRG5 is mediated by its tethered agonist. FASEB J. 2016;30:666–673. doi: 10.1096/fj.15-276220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.15-276220</ArticleId>
            <ArticleId IdType="pubmed">26499266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholz N., Guan C., Nieberler M., Grotemeyer A., Maiellaro I., Gao S., Beck S., Pawlak M., Sauer M., Asan E., et al.  Mechano-dependent signaling by Latrophilin/CIRL quenches cAMP in proprioceptive neurons. eLife. 2017;6:e28360. doi: 10.7554/eLife.28360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.28360</ArticleId>
            <ArticleId IdType="pmc">PMC5548486</ArticleId>
            <ArticleId IdType="pubmed">28784204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fagerberg L., Hallstrom B.M., Oksvold P., Kampf C., Djureinovic D., Odeberg J., Habuka M., Tahmasebpoor S., Danielsson A., Edlund K., et al.  Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell Proteom. 2014;13:397–406. doi: 10.1074/mcp.M113.035600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M113.035600</ArticleId>
            <ArticleId IdType="pmc">PMC3916642</ArticleId>
            <ArticleId IdType="pubmed">24309898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsson M., Zhang C., Méar L., Zhong W., Digre A., Katona B., Sjöstedt E., Butler L., Odeberg J., Dusart P., et al.  A single-cell type transcriptomics map of human tissues. Sci. Adv. 2021;7:eabh2169. doi: 10.1126/sciadv.abh2169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abh2169</ArticleId>
            <ArticleId IdType="pmc">PMC8318366</ArticleId>
            <ArticleId IdType="pubmed">34321199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ludwig M.G., Seuwen K., Bridges J.P. Adhesion GPCR function in pulmonary development and disease. Handb. Exp. Pharmacol. 2016;234:309–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu V., Yeerna H., Nohata N., Chiou J., Harismendy O., Raimondi F., Inoue A., Russell R.B., Tamayo P., Gutkind J.S. Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. J. Biol. Chem. 2019;294:11062–11086. doi: 10.1074/jbc.REV119.005601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.REV119.005601</ArticleId>
            <ArticleId IdType="pmc">PMC6643028</ArticleId>
            <ArticleId IdType="pubmed">31171722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esteves L., Caramelo F., Ribeiro I.P., Carreira I.M., de Melo J.B. Probability distribution of copy number alterations along the genome: An algorithm to distinguish different tumour profiles. Sci. Rep. 2020;10:14868. doi: 10.1038/s41598-020-71859-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-71859-1</ArticleId>
            <ArticleId IdType="pmc">PMC7483770</ArticleId>
            <ArticleId IdType="pubmed">32913269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sriram K., Moyung K., Corriden R., Carter H., Insel P.A. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biol. 2019;17:e3000434.  doi: 10.1371/journal.pbio.3000434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.3000434</ArticleId>
            <ArticleId IdType="pmc">PMC6901242</ArticleId>
            <ArticleId IdType="pubmed">31765370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y.Y., Sweredoski M.J., Huss D., Lansford R., Hess S., Tirrell D.A. Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126. ACS Chem. Biol. 2013;9:334–338. doi: 10.1021/cb400704n.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cb400704n</ArticleId>
            <ArticleId IdType="pmc">PMC3944050</ArticleId>
            <ArticleId IdType="pubmed">24274104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park G.B., Kim D. MicroRNA-503-5p inhibits the CD97-mediated JAK2/STAT3 pathway in metastatic or paclitaxel-resistant ovarian cancer cells. Neoplasia. 2019;21:206–215. doi: 10.1016/j.neo.2018.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2018.12.005</ArticleId>
            <ArticleId IdType="pmc">PMC6355618</ArticleId>
            <ArticleId IdType="pubmed">30622051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Wang Y., Mojumdar K., Zhou Z., Jeong K.J., Mangala L.S., Yu S., Tsang Y.H., Rodriguez-Aguayo C., Lu Y., et al.  A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J. Clin. Investig. 2019;129:5343–5356. doi: 10.1172/JCI123396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI123396</ArticleId>
            <ArticleId IdType="pmc">PMC6877318</ArticleId>
            <ArticleId IdType="pubmed">31682236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh V., Singh L.C., Vasudevan M., Chattopadhyay I., Borthakar B.B., Rai A.K., Phukan R.K., Sharma J., Mahanta J., Kataki A.C., et al.  Esophageal cancer epigenomics and integrome analysis of genome-wide methylation and expression in high risk northeast indian population. OMICS. 2015;19:688–699. doi: 10.1089/omi.2015.0121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/omi.2015.0121</ArticleId>
            <ArticleId IdType="pubmed">26496483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang P.-Y., Liao Y.-P., Wang H.-C., Chen Y.-C., Huang R.-L., Wang Y.-C., Yuan C.-C., Lai H.-C. An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. Oncotarget. 2017;8:53432–53449. doi: 10.18632/oncotarget.18515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.18515</ArticleId>
            <ArticleId IdType="pmc">PMC5581121</ArticleId>
            <ArticleId IdType="pubmed">28881822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieberler M., Kittel R.J., Petrenko A.G., Lin H.H., Langenhan T. Control of adhesion GPCR function through proteolytic processing. Handb. Exp. Pharmacol. 2016;234:83–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinert M., Wobus M., Boltze C., Schütz A., Wahlbuhl M., Hamann J., Aust G. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol. 2002;161:1657–1667. doi: 10.1016/S0002-9440(10)64443-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64443-4</ArticleId>
            <ArticleId IdType="pmc">PMC1850798</ArticleId>
            <ArticleId IdType="pubmed">12414513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogl U.M., Öhler L., Rasic M., Frischer J.M., Modak M., Stöckl J. Evaluation of prognostic immune signatures in patients with breast, colorectal and pancreatic cancer receiving chemotherapy. Anticancer Res. 2017;37:1947–1955. doi: 10.21873/anticanres.11535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/anticanres.11535</ArticleId>
            <ArticleId IdType="pubmed">28373465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jinawath N., Vasoontara C., Jinawath A., Fang X., Zhao K., Yap K.-L., Guo T., Lee C.S., Wang W., Balgley B.M., et al.  Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS ONE. 2010;5:e11198.  doi: 10.1371/journal.pone.0011198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0011198</ArticleId>
            <ArticleId IdType="pmc">PMC2887843</ArticleId>
            <ArticleId IdType="pubmed">20585448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aust G., Eichler W., Laue S., Lehmann I., Heldin N.-E., Lotz O., Scherbaum W.A., Dralle H., Hoang-Vu C. CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Res. 1997;57:1798–1806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9135025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aust G., Steinert M., Schütz A., Wahlbuhl M., Hamann J., Wobus M. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic and esophageal carcinomas. Am. J. Clin. Pathol. 2002;118:699–707. doi: 10.1309/A6AB-VF3F-7M88-C0EJ.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/A6AB-VF3F-7M88-C0EJ</ArticleId>
            <ArticleId IdType="pubmed">12428789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Lei L., Wang S., Gu D., Zhang J. Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J. Biomed. Biotechnol. 2012;2012:587672. doi: 10.1155/2012/587672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/587672</ArticleId>
            <ArticleId IdType="pmc">PMC3324160</ArticleId>
            <ArticleId IdType="pubmed">22547928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoang-Vu C., Bull K., Schwarz I., Krause G., Schmutzler C., Aust G., Köhrle J., Dralle H. Regulation of CD97 protein in thyroid carcinoma. J. Clin. Endocrinol. Metab. 1999;84:1104–1109. doi: 10.1210/jc.84.3.1104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.84.3.1104</ArticleId>
            <ArticleId IdType="pubmed">10084602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugli A., Zlobec I., Berger M.D., Kirsch R., Nagtegaal I.D. Tumour budding in solid cancers. Nat. Rev. Clin. Oncol. 2021;18:101–115. doi: 10.1038/s41571-020-0422-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-020-0422-y</ArticleId>
            <ArticleId IdType="pubmed">32901132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galle J., Sittig D., Hanisch I., Wobus M., Wandel E., Loeffler M., Aust G. Individual cell-based models of tumor–environment interactions. Multiple effects of CD97 on tumor invasion. Am. J. Pathol. 2006;169:1802–1811. doi: 10.2353/ajpath.2006.060006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2006.060006</ArticleId>
            <ArticleId IdType="pmc">PMC1780199</ArticleId>
            <ArticleId IdType="pubmed">17071601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., Knuechel R., Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA. 2001;98:10356–10361. doi: 10.1073/pnas.171610498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.171610498</ArticleId>
            <ArticleId IdType="pmc">PMC56965</ArticleId>
            <ArticleId IdType="pubmed">11526241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hlubek F., Brabletz T., Budczies J., Pfeiffer S., Jung A., Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int. J. Cancer. 2007;121:1941–1948. doi: 10.1002/ijc.22916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.22916</ArticleId>
            <ArticleId IdType="pubmed">17631641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wobus M., Huber O., Hamann J., Aust G. CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway. Mol. Carcinog. 2006;45:881–886. doi: 10.1002/mc.20262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.20262</ArticleId>
            <ArticleId IdType="pubmed">16929497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safaee M., Clark A.J., Oh M.C., Ivan M.E., Bloch O., Kaur G., Sun M.Z., Kim J.M., Oh T., Berger M.S., et al.  Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS ONE. 2013;8:e62765.  doi: 10.1371/journal.pone.0062765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0062765</ArticleId>
            <ArticleId IdType="pmc">PMC3637305</ArticleId>
            <ArticleId IdType="pubmed">23658650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallawaaratchy D.M., Buckland M.E., McDonald K.L., Li C.C., Ly L., Sykes E.K., Christopherson R.I., Kaufman K.L. Membrane proteome analysis of glioblastoma cell invasion. J. Neuropathol. Exp. Neurol. 2015;74:425–441. doi: 10.1097/NEN.0000000000000187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0000000000000187</ArticleId>
            <ArticleId IdType="pubmed">25853691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safaee M., Fakurnejad S., Bloch O., Clark A.J., Ivan M.E., Sun M.Z., Oh T., Phillips J.J., Parsa A.T. Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells. PLoS ONE. 2015;10:e0111532.  doi: 10.1371/journal.pone.0111532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0111532</ArticleId>
            <ArticleId IdType="pmc">PMC4340952</ArticleId>
            <ArticleId IdType="pubmed">25714433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J.K., Lubelski D., Schonberg D.L., Wu Q., Hale J.S., Flavahan W.A., Mulkearns-Hubert E.E., Man J., Hjelmeland A.B., Yu J., et al.  Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death Differ. 2014;21:1325–1339. doi: 10.1038/cdd.2014.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2014.65</ArticleId>
            <ArticleId IdType="pmc">PMC4085538</ArticleId>
            <ArticleId IdType="pubmed">24832468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirkowska P., Hofmann A., Sedek L., Slamova L., Mejstrikova E., Szczepanski T., Schmitz M., Cario G., Stanulla M., Schrappe M., et al.  Leukemia surfaceome analysis reveals new disease-associated features. Blood. 2013;121:e149–e159. doi: 10.1182/blood-2012-11-468702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2012-11-468702</ArticleId>
            <ArticleId IdType="pubmed">23649467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito Y., Kitamura H., Hijikata A., Tomizawa-Murasawa M., Tanaka S., Takagi S., Uchida N., Suzuki N., Sone A., Najima Y., et al.  Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2010;2:17ra9. doi: 10.1126/scitranslmed.3000349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3000349</ArticleId>
            <ArticleId IdType="pmc">PMC3005290</ArticleId>
            <ArticleId IdType="pubmed">20371479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coustan-Smith E., Song G., Clark C., Key L., Liu P., Mehrpooya M., Stow P., Su X., Shurtleff S., Pui C.H., et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117:6267–6276. doi: 10.1182/blood-2010-12-324004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2010-12-324004</ArticleId>
            <ArticleId IdType="pmc">PMC3122946</ArticleId>
            <ArticleId IdType="pubmed">21487112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin G.H., Roy N., Chakraborty S., Desrichard A., Chung S.S., Woolthuis C.M., Hu W., Berezniuk I., Garrett-Bakelman F.E., Hamann J., et al.  CD97 is a critical regulator of acute myeloid leukemia stem cell function. J. Exp. Med. 2019;216:2362–2377. doi: 10.1084/jem.20190598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20190598</ArticleId>
            <ArticleId IdType="pmc">PMC6781010</ArticleId>
            <ArticleId IdType="pubmed">31371381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coustan-Smith E., Song G., Shurtleff S., Yeoh A.E.-J., Chng W.J., Chen S.P., Rubnitz J.E., Pui C.-H., Downing J.R., Campana D. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight. 2018;3:e98561. doi: 10.1172/jci.insight.98561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.98561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houtsma R., van der Meer N.K., Meijer K., Morsink L., Hogeling S.M., Woolthuis C., Ammatuna E., Nijk M., de Boer B., Huls G., et al.  CombiFlow: Combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones. Blood Adv. 2022;6:2129–2149. doi: 10.1182/bloodadvances.2021005018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2021005018</ArticleId>
            <ArticleId IdType="pmc">PMC9006304</ArticleId>
            <ArticleId IdType="pubmed">34543390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsiao C.C., Keysselt K., Chen H.Y., Sittig D., Hamann J., Lin H.H., Aust G. The Adhesion GPCR CD97 inhibits apoptosis. Int. J. Biochem. Cell Biol. 2015;65:197–208. doi: 10.1016/j.biocel.2015.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biocel.2015.06.007</ArticleId>
            <ArticleId IdType="pubmed">26071181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safaee M.M., Wang E.J., Jain S., Chen J.-S., Gill S., Zheng A.C., Garcia J.H., Beniwal A.S., Tran Y., Nguyen A.T., et al.  CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma. Sci. Rep. 2022;12:1464. doi: 10.1038/s41598-022-05259-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-022-05259-y</ArticleId>
            <ArticleId IdType="pmc">PMC8795421</ArticleId>
            <ArticleId IdType="pubmed">35087132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sethi N., Kang Y. Unravelling the complexity of metastasis—Molecular understanding and targeted therapies. Nat. Rev. Cancer. 2011;11:735–748. doi: 10.1038/nrc3125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3125</ArticleId>
            <ArticleId IdType="pubmed">21941285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiam-Galvez K.J., Allen B.M., Spitzer M.H. Systemic immunity in cancer. Nat. Rev. Cancer. 2021;21:345–359. doi: 10.1038/s41568-021-00347-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-021-00347-z</ArticleId>
            <ArticleId IdType="pmc">PMC8034277</ArticleId>
            <ArticleId IdType="pubmed">33837297</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
